Anthony Gregg Lapointe
CIK: 0001331860
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Oct 12, 2026SNGX
SOLIGENIX, INC.
Disposition(D)DirectStock Option (Right to Buy)
63 shares- - Oct 12, 2026SNGX
SOLIGENIX, INC.
Disposition(D)DirectStock Option (Right to Buy)
192 shares- - Oct 12, 2026SNGX
SOLIGENIX, INC.
Disposition(D)DirectStock Option (Right to Buy)
121 shares- - Oct 12, 2026SNGX
SOLIGENIX, INC.
Disposition(D)DirectStock Option (Right to Buy)
128 shares- - Oct 12, 2026SNGX
SOLIGENIX, INC.
Disposition(D)DirectStock Option (Right to Buy)
74 shares- - Oct 12, 2026SNGX
SOLIGENIX, INC.
Disposition(D)DirectStock Option (Right to Buy)
54 shares- - Sep 17, 2026SNGX
SOLIGENIX, INC.
Award(A)DirectStock Option (Right to Buy)
78.9K shares- - May 15, 2026RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct5.8K shares- - Jan 23, 2026ATXS
Astria Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
26.6K shares- - Jan 23, 2026ATXS
Astria Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
16.7K shares- - Jan 23, 2026ATXS
Astria Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
8.3K shares- - Jan 23, 2026ATXS
Astria Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
14.1K shares- - Jan 23, 2026ATXS
Astria Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
14.1K shares- - Jun 20, 2025SNGX
SOLIGENIX, INC.
Award(A)DirectStock Option (Right to Buy)
17.6K shares- - Jun 11, 2025ATXS
Astria Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
26.6K shares- - May 23, 2025RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct2.5K shares- - Dec 12, 2024SNGX
SOLIGENIX, INC.
Award(A)DirectStock Option (Right to Buy)
8.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 12, 2026 |  SNGX SOLIGENIX, INC. | Disposition(D) Stock Option (Right to Buy) | 63 | - | - | Direct |
| Oct 12, 2026 | SNGX SOLIGENIX, INC. | Disposition(D) Stock Option (Right to Buy) | 192 | - | - | Direct |
| Oct 12, 2026 | SNGX SOLIGENIX, INC. | Disposition(D) Stock Option (Right to Buy) | 121 | - | - | Direct |
| Oct 12, 2026 | SNGX SOLIGENIX, INC. | Disposition(D) Stock Option (Right to Buy) | 128 | - | - | Direct |
| Oct 12, 2026 | SNGX SOLIGENIX, INC. | Disposition(D) Stock Option (Right to Buy) | 74 | - | - | Direct |
| Oct 12, 2026 | SNGX SOLIGENIX, INC. | Disposition(D) Stock Option (Right to Buy) | 54 | - | - | Direct |
| Sep 17, 2026 | SNGX SOLIGENIX, INC. | Award(A) Stock Option (Right to Buy) | 78,947 | - | - | Direct |
| May 15, 2026 |  RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 5,750 | - | $0 | Direct |
| Jan 23, 2026 |  ATXS Astria Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 26,550 | - | - | Direct |
| Jan 23, 2026 | ATXS Astria Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 16,666 | - | - | Direct |
| Jan 23, 2026 | ATXS Astria Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 8,333 | - | - | Direct |
| Jan 23, 2026 | ATXS Astria Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 14,100 | - | - | Direct |
| Jan 23, 2026 | ATXS Astria Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 14,100 | - | - | Direct |
| Jun 20, 2025 | SNGX SOLIGENIX, INC. | Award(A) Stock Option (Right to Buy) | 17,647 | - | - | Direct |
| Jun 11, 2025 | ATXS Astria Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 26,550 | - | - | Direct |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 2,500 | - | - | Direct |
| Dec 12, 2024 | SNGX SOLIGENIX, INC. | Award(A) Stock Option (Right to Buy) | 8,646 | - | - | Direct |
1-17 of 17 transactions
About LAPOINTE ANTHONY GREGG
LAPOINTE ANTHONY GREGG (SEC CIK 0001331860) files insider reports with the SEC as Director of SOLIGENIX, INC. (SNGX), Director of RIGEL PHARMACEUTICALS INC (RIGL) and Director of Astria Therapeutics, Inc. (ATXS).
Signal8 holds 8 ownership filings by LAPOINTE ANTHONY GREGG, all Form 4s, filed between Dec 13, 2024 and Oct 13, 2026. Those filings report 17 transactions, from Dec 12, 2024 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on LAPOINTE ANTHONY GREGG's filings is in PRINCETON, NJ.
Recent filings by LAPOINTE ANTHONY GREGG
- Oct 12, 2026: Disposition to issuer transactions of SNGX derivative securities (6 lines, Form 4, code D).
- Sep 17, 2026: Grant or award of SNGX derivative securities (Form 4, code A).
- May 15, 2026: Grant or award of RIGL shares (Form 4, code A).
- Jan 23, 2026: Disposition to issuer transactions of ATXS derivative securities (5 lines, Form 4, code D).
- Jun 20, 2025: Grant or award of SNGX derivative securities (Form 4, code A).
Other insiders filing for SOLIGENIX, INC. (SNGX)
- ZELDIS JEROME B, Director
- RUBIN ROBERT J., Director
- Parks Diane L., Director
- Donini Oreola, CSO
- Guarino Jonathan L., CFO
- SCHABER CHRISTOPHER J, CHAIRMAN, CEO AND PRESIDENT